FAM19A4基因启动子甲基化检测在宫颈癌及其癌前病变筛查的研究

宫颈癌是最常见的妇科恶性肿瘤之一。目前人乳头瘤病毒(HPV)检测及细胞学检查是宫颈癌及其癌前病变(CCPL)的主要筛查手段。由于上述传统筛查方法,仍然存在对CCPL漏诊的风险,因此寻找有效识别CCPL的特异性分子标志物,具有重要临床意义。对具有序列相似性家族19成员A4(FAM19A4)基因启动子甲基化定量检测,可有效检出CCPL组织,较传统筛查方法有较高特异度,有望成为CCPL筛查的特异性分子标志物。笔者拟就FAM19A4基因启动子甲基化定量检测,在CCPL筛查中应用的最新研究现状进行阐述,旨在为进一步推进CCPL筛查方法的开发,提供思路。

Current research status of methylation quantification of FAM19A4 gene promoter in cervical cancer and its precancerous lesion screening

Cervical cancer is one of the most common gynecologic malignancies.At present,human papillomavirus(HPV)and cytological test are the main screening methods for cervical cancer and its precancerous lesions(CCPL).As the above traditional screening methods have the risk of missed diagnosis of CCPL,it is of great significance to find specific molecular markers that can effectively identify CCPL.Methylation quantification of family with sequence similarity 19 member A4(FAM19A4)gene promoter can effectively detect CCPL tissues,with higher specificity than traditional screening methods,and is expected to be a specific molecular marker for screening CCPL.The authors intend to describe methylation quantification of FAM19A4 gene promoter in CCPL screening in order to provide ideas for further promoting the development of CCPL screening methods.